Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

BACKGROUND: Chk1 inhibitors are currently in clinical trials as putative potentiators of cytotoxic chemotherapy drugs. Chk1 inhibitors may exhibit single agent anti-tumor activity in cancers with underlying DNA repair, DNA damage response or DNA replication defects. METHODS: Here we describe the cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryant, Christopher, Rawlinson, Rebecca, Massey, Andrew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137066/
https://www.ncbi.nlm.nih.gov/pubmed/25104095
http://dx.doi.org/10.1186/1471-2407-14-570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137066/
https://www.ncbi.nlm.nih.gov/pubmed/25104095
http://dx.doi.org/10.1186/1471-2407-14-570

Ejemplares similares